A randomized, double-blind, placebo-controlled study of 4-hydroxytamoxifen topical GEL in women with mammographically dense breasts
Ended Awarded Last action
- Contract number
- HHSN26100011
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,186,265
Award facts
- Opportunity
-
- FF2015 Solicitation number
- Contract value 100% obligated
- $2,186,264.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$95,578 | |
| Funding Only Action | -$69,445 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $95,578 | |
| Exercise an Option | $691,865 | |
| Funding Only Action | $790,348 | |
| Change Order | $0 | |
| Original award | $773,497 |
About this award
This is a contract awarded by the National Cancer Institute (NCI), an institute within the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center. The $2,186,264.78 contract is for a randomized, double-blind, placebo-controlled study of a topical breast cancer prevention agent, 4-hydroxytamoxifen gel, in women with dense breast tissue. This contract was issued under the NCI's Cancer Prevention Agent Development Program, which supports early phase clinical trials of novel cancer prevention strategies. The University of Texas System, which includes MD Anderson, frequently receives prime and subcontract awards from federal agencies like NIH to support cancer research, treatment, and prevention initiatives across its institutions. This contract does not have a small business set-aside designation.
Quick answers
Who was awarded contract HHSN26100011?
HHSN26100011 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 19, 2016.
How much is contract HHSN26100011 worth?
The government has obligated $2,186,265 on HHSN26100011.
Is contract HHSN26100011 an order under another contract?
Yes. HHSN26100011 is a delivery order under HHSN261201200034I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100011 competed?
The extent of competition for HHSN26100011 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award